Literature DB >> 6478735

Tolrestat kinetics.

D R Hicks, M Kraml, M N Cayen, J Dubuc, S Ryder, D Dvornik.   

Abstract

The kinetics of tolrestat, a potent inhibitor of aldose reductase, were examined. Serum concentrations of tolrestat and of total 14C were measured after dosing normal subjects and subjects with diabetes with 14C-labeled tolrestat. In normal subjects, tolrestat was rapidly absorbed and disappearance from serum was biphasic. Distribution and elimination t 1/2s were approximately 2 and 10 to 12 hr, respectively, after single and multiple doses. Unchanged tolrestat accounted for the major portion of 14C in serum. Radioactivity was rapidly and completely excreted in urine and feces in an approximate ratio of 2:1. Findings were much the same in subjects with diabetes. In normal subjects, the kinetics of oral tolrestat were independent of dose in the 10 to 800 mg range. Repetitive dosing did not result in unexpected cumulation. Tolrestat was more than 99% bound to serum protein; it did not compete with warfarin for binding sites but was displaced to some extent by high concentrations of tolbutamide or salicylate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6478735     DOI: 10.1038/clpt.1984.209

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.

Authors:  A J Boulton; S Levin; J Comstock
Journal:  Diabetologia       Date:  1990-07       Impact factor: 10.122

Review 3.  Physiological and Pathological Roles of Aldose Reductase.

Authors:  Mahavir Singh; Aniruddh Kapoor; Aruni Bhatnagar
Journal:  Metabolites       Date:  2021-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.